State Opioid Treatment Authorities’ Meeting

 

2016 header

Sunday, October 30, 2016
8:30 a.m. – 5:30 p.m.
(Closed Session for State and Federal Officials)

  • Mitra Ahadpour, MD, Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), Rockville, MD
  • Melinda Campopiano von Klimo, MD, Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), Rockville, MD
  • Anthony Campbell, DO, Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), Rockville, MD
  • Wilmarie Hernandez, Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), Rockville, MD
  • Jinhee Lee, PharmD, Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), Rockville, MD
  • Brandon Johnson, MBA, Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), Rockville, MD
  • Mary Lou Ojeda, MS, Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), Rockville, MD
  • Sidney Hairston, MSN, Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), Rockville, MD
  • Ivette Ruiz, MS-CRP, Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), Rockville, MD
  • Nichole Smith, MSHS, Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), Rockville, MD
  • Drug Enforcement Administration (DEA)
  • State Opioid Treatment Authorities (SOTAs)

Federal officials, including Substance Abuse Mental Health Services Administration (SAMHSA), the Drug Enforcement Administration (DEA), and State Opioid Treatment Authorities, will convene to share information and discuss a variety of topics of interest to both SAMHSA and the States. Issues of mutual concern in the approval and monitoring of Opioid Treatment Programs, including clinical, administrative, financing, and regulatory policy topics, will be discussed to improve and coordinate joint oversight.

Sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA)

Pin It on Pinterest

Share This